Page last updated: 2024-08-25

cholest-5-ene-3,4-diol and Koch's Disease

cholest-5-ene-3,4-diol has been researched along with Koch's Disease in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Aklillu, E; Bakari, M; Bertilsson, L; Burhenne, J; Diczfalusy, U; Janabi, M; Minzi, O; Mugusi, F; Mugusi, S; Ngaimisi, E; Riedel, KD; Sasi, P; Suda, A; Ueda, N	1

Other Studies

1 other study(ies) available for cholest-5-ene-3,4-diol and Koch's Disease

Article	Year
Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment. The Journal of antimicrobial chemotherapy, 2014, Volume: 69, Issue:12 Topics: Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP3A; Female; Genotype; HIV Infections; Humans; Hydroxycholesterols; Male; Middle Aged; Rifampin; Tuberculosis	2014

Article

Year

Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment.

The Journal of antimicrobial chemotherapy, 2014, Volume: 69, Issue:12

Topics: Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP3A; Female; Genotype; HIV Infections; Humans; Hydroxycholesterols; Male; Middle Aged; Rifampin; Tuberculosis

2014